Back to search results

Stomach Cancer, Gastroesophageal Junction Cancer (GEJ), Advanced Cancer

A Study of LY2801653 in Participants With Advanced Cancer

JSBA | {{ defaultRegistry.registryAnchorText }} NCT01285037 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to determine a recommended phase 2 dose of LY2801653 that may be safely given to participants with gastric cancer when taken with ramucirumab.

Completed Study

The results of this study are not yet available.

Time Commitment

Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study


Male Female


18+ years
  • Participant must have stomach cancer, including stomach adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma (participants with adenocarcinoma of the distal esophagus are eligible if the primary tumor involves the GEJ) confirmed by histology or cytology
  • Participant must provide a mandatory tumor tissue sample, when safe and feasible, for biomarker analysis
  • Participant must be able to swallow capsules or have the study drug crushed and administered through a feeding tube
  • Female participants must not be pregnant or breastfeeding
  • Participants must not have liver cancer, liver cirrhosis with a Child-Pugh stage of B or higher, or received a liver transplant

Where This Study Took Place Tool Tip Icon

Where This Study Took Place Tool Tip Icon

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.